MXPA97006416A - Composition to control parasi - Google Patents

Abstract

The present invention relates to a composition for controlling parasites, in and on animals, which comprises, an active ingredient, a combination, in varying proportions, of at least one parasiticidally active compound, in free form or in salt form, selected from the class of substances of N-phenyl-N'-benzoyl-urea, and at least one parasiticidally active compound, in free form or in salt form, selected from the classes of substances of milbemycin, avermectin, milbemycin oxime, moxidectin, ivermectin, abamectin and doramectin, to a method to control these parasites, to a process for the preparation of this composition, and to the use of this composition

Description

COMPOSITION TO CONTROL PARASITES The present invention relates to a composition comprising a combination of at least two parasiticidally active substances, and which is suitable for controlling pests within and on animals, to a method for controlling these parasites, to a process for the preparation of this composition. , and to the use of this composition. As is known, the life cycles of many parasites, in and on animals, are very complicated, which makes the control of these parasites, which without their effective control often cause considerable damage, for example, economic, is extraordinarily difficult . Within the scope of the present invention, the parasites will be understood to comprise ectoparasites, as well as endoparasites. For example, ticks, which are representatives of ectoparasites, can feed exclusively on a host animal, or also on several hosts. They settle on the host animal, and they feed on their blood. The females, completely replete with blood, fall from the host animal, and then place a large number of eggs in a suitable niche in the vicinity. Then the developing larvae search for a new host animal, in order to develop, going through the nymph stage to adults, and once again they become completely filled with blood. Certain species can migrate from a host animal to a second and even a third host animal. Ticks, which are of economic significance from the etiological point of view, belong mainly to the genera Amblyomma, Boophilus, Hyalomma, Ixodes, Rhipicephalus or Dermacentor; the species Boophilus microplus and B. annulatus are especially involved, more especially B. Microplus. They are also responsible for the transmission of numerous diseases that can affect humans and animals. In particular, bacterial, protozoal, rheumatism, and viral diseases are transmitted. The causative organisms of these diseases are transmitted especially by ticks that feed on more than one host. These diseases can lead to the weakening or even death of host animals. Normally they cause high economic losses, for example, as a result of the meat of the producer cattle that loses value, damaging the usable skin, or reducing the production of milk. Ticks are normally controlled by treating the affected animals with an acaricidal active composition in response to a real infestation, that is, curatively. The presentation of ticks, for example, in the pasture land, depends very much on the conditions of the seasonal climate, and the final infestation of the host animals depends, in addition, on their resistance to ticks. This means that it is difficult and time-consuming to prevent ticks, since, among other things, the risk of infestation by pests and the resistance of animals to them can only be estimated with difficulty. In addition, when a preventive control of the parasites is tested, the potential infestation must be monitored over a relatively long period, which causes additional problems. However, the reason why preventive control would be desired is the fact that relatively large damage has already occurred relatively frequently by the time the curative control begins to act. Fleas, another example of representatives of ectoparasites, also have a very complex life cycle. For example, adult cat fleas (Ctenocephalides felis) and dog fleas (C. canis) usually live on the skin of the host cat and the host dog. They feed on the blood of the host animal, and lay their eggs in their hair. Since these eggs do not stick on their own, however, they usually fall off early and can be found on the floor, on the carpet, in the basket of the dog or in the basket of the cat, in a chair used by the animal, in the garden, and in all other places with which the infested animal comes into contact. This means that the entire area where the animal lives is contaminated with flea eggs, from which, in two days, the larvae develop. In the case of larvae, a distinction is made between three stages of development, each of which lasts three days. In the last stage, the larvae spin their cocoons and change to pupae, from which the young and mature fleas develop. The young adult fleas remain there until they detect the presence of an acceptable host animal, then emerge from their cocoons and try to jump on the host animal. Therefore, it takes approximately three weeks before a young adult flea is able to re-infest the host animal, developing from an egg. However, the young flea may remain in its cocoon for months, possibly up to a year. On the other hand, under less than optimal conditions, development from the egg to the young adult flea may take 4 to 5 months. Fleas require blood as food to reach sexual maturity in order to reproduce. Flea larvae feed mainly on the excretions of adult fleas that live in the host animal. These excretions contain high proportions of undigested blood. The infestation with fleas of an animal, especially of a dog or a cat, has unpleasant accompaniments not only for the animal, but also for the one that takes care of the animal. These unpleasant effects lead, as regards the animal, for example, to local irritation, to an annoying itching, or even to allergies, and often cause intense irritation. In addition, an animal infested with fleas is constantly exposed to the risk of being infected with representatives of Dipylidiu spp., That is, with solitaires, which are transmitted by fleas. In addition, fleas and their excretions can also lead to skin disorders in the form of allergy of many people, which in many cases forces them to stop having the animal. Effective control of fleas in animals, especially in livestock and in pets, especially in dogs and cats, has therefore been desirable since time immemorial. The long life cycle described above, a large proportion of which takes place away from the host animal, has a significant effect on the success control of fleas in the host animal. Only when the described cycle can be broken, that is, when the numerous flea eggs and flea larvae present in the environment of the host animal can be destroyed, is the animal protected from continuous reinfestation by adult parasites. However, none of the known methods for flea control gives complete satisfaction, especially since most of the known control methods rely on the compositions containing the active substance that is being applied to the habitat of the different stages of the process. flea. However, in view of the complex life cycle of fleas, this application is very laborious, time consuming and / or unreliable, that is, it is not particularly promising in the long term. Only in the short term is it possible to achieve some relief with these known methods. For example, if the control is directed to the treatment of fully fledged fleas on the skin, which is normally done by applying a flea composition to the skin of the host animal, the different juvenile stages of the fleas, which live not only in the skin of the animal, but also mainly in all the places with which the infested animal comes into contact, they are totally left out of consideration. A large number of conventional control methods are known, however, have several drawbacks. For exampleIf combs are used for fleas, which are superficially encoded with an insecticide, the animal's caretaker has to comb the animal in an intense and frequent manner. The use of soos against corresponding fleas is not possible in many cases, since most infested animals can only bathe with difficulty, if possible. Moreover, the effect of this bathing treatment lasts about a week at most. The same problems must be taken into account when using rubbing or oil rinsing. In general, animals do not submit themselves, without any resistance, to the use of powders. It is virtually inevitable that the animal's keeper also comes into contact with the composition to a greater or lesser degree. When sprays are used, most animals, especially cats, take flight or react aggressively to the mere noise of the sprayer. In addition, the sprayers also have the drawbacks mentioned in relation to the powders, to which is added that they are dispersed even finer in the atmosphere and, therefore, can be inhaled by the caregiver and by the animal. Frequently, fleas are also controlled by so-called flea collars, which show a good temporary effect. However, a weakness that is found with this treatment is the locally limited application. In general, conventional methods, which aim to annihilate the adult flea, provide unsatisfactory results mainly because they depend on the patience and ability of the caregiver to deal with the infested host animal. Another aspect that has not been given enough attention in the case of conventional methods is the fact that, due to the particular life cycle of the fleas, the host animals become infested again and again, on the one hand due to its contact with flea eggs, flea larvae, and young adult fleas in the environment of animals, which is inevitable and, on the other hand, because many animals come into contact again and again with infested members of their own species. Using the known methods, continuous reinfestation is not adequately prevented, or prevention can only be achieved with high concentrations of application of the parasiticide compositions. In many regions of the earth, the conditions under which animals are kept, especially domestic animals and pets, greatly encourage the extension not only of ectoparasites, but also, in particular, of endoparasites. These endoparasites especially include pests generally referred to as helminths, which can infest, for example, domestic animals, such as pigs, sheep, cows, calves, goats, horses, dogs, cats or poultry. Helminthiasis is a serious economic and hygiene problem in domestic animals. It leads to anemia, poor nutrition, lack of firmness, weight loss and / or damage to the walls of the intestinal tract or other organs, and if left untreated, can result in the death of the affected animal. Among the helminths, especially the group of roundworms (ne ottos) causes a serious infection of animals. The representatives of the genera Nematodiurus, Copperia or Oesophagostomum live in the intestines, while those of the genera Haemonchus or Ostertagia live in the stomach, and those of the genus Dictyocaulus can be found in the lungs. Parasites of the families Filariidae or Setariidae affect mainly the heart, the blood vessels, and the lymphatic vessels. Other examples of endoparasites capable of causing great damage, especially in dogs, are the representatives of the genus Dirofilaria, especially Dirofilaria immitis (heartworm). As mentioned earlier in this, a large number of compositions for controlling parasites inside and on animals have already been proposed. Also, as mentioned hereinabove, the properties of these known compositions are not always entirely satisfactory and, consequently, there is a need to make available other parasiticidally active compositions, especially for the control of insects, representatives of the Acariña order. parasitic worms. This problem is solved according to the invention, by the provision of the present composition. According to the above, the present invention relates to a composition for controlling parasites, within and on animals, which comprises, as an active ingredient, a combination, in varying proportions, of at least one parasiticidally active compound, in free or in salt form, selected from the class of substances of N-phenyl-N'-benzoyl-urea, and at least one parasiticidally active compound, in free form or in salt form, selected from the classes of substances of milbe ycin, avermectin, milbemycin oxime, moxidectin, ivermectin, abamectin and doramectin. The invention preferably relates to a corresponding composition comprising, as an active ingredient, at least one compound of the formula: where: R? is halogen, alkyl of 1 to 8 carbon atoms, cycloalkyl of 3 to 8 carbon atoms, halocycloalkyl of 3 to 8 carbon atoms, haloalkyl of 1 to 8 carbon atoms, alkoxy of 1 to 8 carbon atoms, alkoxy of 1 to 4 carbon atoms-alkyl of 1 to 4 carbon atoms, or haloalkoxy of 1 to 8 carbon atoms; R2 is halogen, alkyl of 1 to 8 carbon atoms, cycloalkyl of 3 to 8 carbon atoms, haloalkyl of 1 to 8 carbon atoms, halocycloalkyl of 3 to 8 carbon atoms, alkoxy of 1 to 8 carbon atoms, cycloalkoxy from 3 to 8 carbon atoms, halocycloalkoxy of 3 to 8 carbon atoms, haloalkoxy of 1 to 8 carbon atoms, aryloxy or heteroaryloxy, aryloxy or substituted heteroaryloxy, or a group -CH2-0-N = C (R3) R4; R3 and R are each, independently of the other, alkyl of 1 to 4 carbon atoms, cycloalkyl of 3 to 8 carbon atoms, or aryl, each of which is unsubstituted or substituted; m is from 0 to 5, where, when m is greater than 1, the radicals R? they are the same or different; and n is from 0 to 5, wherein, when n is greater than 1, the radicals R2 are the same or different; in free form or in salt form, and at least one compound of the formula: wherein it is alkyl of 1 to 4 carbon atoms, or alkenyl of 2 to 4 carbon atoms; the bond between atoms 22 and 23 is a single bond or a double bond, -X- is a group R6 is hydrogen, alkyl of 1 to 8 carbon atoms, unsubstituted or substituted, unsubstituted or substituted aryl, -C (= 0) R17 or -Si (R18) (R19) (R2D); R7 is hydrogen or hydroxy, where R7 is hydrogen when the bond between atoms 22 and 23 is a double bond; R8 is hydrogen, alkyl of 1 to 8 carbon atoms, alkenyl of 2 to 8 carbon atoms, alkynyl of 2 to 8 carbon atoms, aryl, substituted aryl, or a group -OR9 or -SR9; R9 is alkyl of 1 to 8 carbon atoms, alkenyl of 2 to 8 carbon atoms, alkynyl of 2 to 8 carbon atoms, aryl, C (= 0) R16, alkyl of 1 to 8 carbon atoms substituted, alkenyl of 2 to 8 carbon atoms, alkynyl of 2 to 8 carbon atoms, or aryl, or unsubstituted or substituted heterocyclyl; R10 is hydrogen, alkyl of 1 to 8 carbon atoms unsubstituted or substituted, arylalkyl of 1 to 4 carbon atoms, -CHaJoCORn or -S02-R15; R1X is hydrogen, alkyl of 1 to 8 carbon atoms, arylalkyl of 1 to 8 carbon atoms, alkenyl of 2 to 8 carbon atoms, alkynyl of 2 to 8 carbon atoms, alkoxy of 1 to 8 carbon atoms, alkenyloxy from 2 to 8 carbon atoms, alkynyloxy of 2 to 8 carbon atoms, aryl, aryloxy -N (R12) R13, - (CH2) pCOOR14, or alkyl of 1 to 8 carbon atoms, or alkoxy of 1 to 8 atoms carbon substituted by alkoxy of 1 to 4 carbon atoms, halogen, or by nitro, or aryl, aryloxy or arylalkyl of 1 to 8 carbon atoms substituted by alkyl of 1 to 4 carbon atoms, haloalkyl of 1 to 4 carbon atoms carbon, alkoxy of 1 to 4 carbon atoms, haloalkoxy of 1 to 4 carbon atoms, halogen, or by nitro; R12 and R13 are each, independently of the other, hydrogen, alkyl of 1 to 8 carbon atoms, phenyl, or alkyl of 1 to 8 carbon atoms, or phenyl substituted by alkoxy of 1 to 4 carbon atoms, halogen or nitro; R14 is hydrogen or unsubstituted or substituted alkyl of 1 to 8 carbon atoms; R15 is alkyl of 1 to 8 carbon atoms or aryl, each of which is unsubstituted or substituted; R16 is hydrogen, alkyl of 1 to 8 carbon atoms, alkoxy of 1 to 8 carbon atoms, or aryl, each of which is unsubstituted or substituted; R17 is hydrogen, alkyl of 1 to 8 carbon atoms, alkoxy of 1 to 8 carbon atoms, or aryl, each of which is unsubstituted or substituted; R18, R19 and R20 are each, independently of the others, alkyl of 1 to 8 carbon atoms, alkoxy of 1 to 8 carbon atoms, or aryl, each of which is unsubstituted or substituted; or is 0, 1, 2, 3 or 4; and p is 0, 1, 2, 3 or 4; in free form or in salt form. A compound I or II, having at least one basic center, can form, for example, acid addition salts. These acid addition salts are formed, for example, with strong inorganic acids, such as mineral acids, for example, perchloric acid, sulfuric acid, nitric acid, nitrous acid, a phosphoric acid or a hydrohalic acid, with strong organic carboxylic acids , such as alkane acids of 1 to 4 carbon atoms unsubstituted or substituted, for example, substituted by halogen, for example, acetic acid, or unsaturated or saturated dicarboxylic acids, for example, oxalic acid, malonic acid, succinic acid, aleic acid, fumaric acid or phthalic acid, or hydroxycarboxylic acids, for example, ascorbic acid, lactic acid, malic acid, tartaric acid or citric acid; 6 benzoic acid, or with organic sulphonic acids, such as alkane acids of 1 to 4 carbon atoms- or aryl-sulfonic acids unsubstituted or substituted, for example, substituted by halogen, for example, methan- or p-toluenesulfonic acid. A compound I or II, which has at least one acid group, can form salts with bases. Salts with suitable bases are, for example, metal salts, salts such as alkali metal salts or alkaline earth metal salts, for example, sodium salts, potassium salts or magnesium salts, or salts with ammonia or with an organic amine , such as morpholine, piperidine, pyrrolidine, a mono-, di- or tri-lower alkyl amine, for example, ethyl-, diethyl-, triethyl- or dimethyl-propyl amine, or a mono-, di- or tri- amine amine. lower hydroxy-alkyl, for example, mono-, di- or tri-ethanolic amine. Moreover, corresponding internal salts can also be formed, where possible. Preferred salts within the scope of the invention are veterinarily convenient salts. Due to the close relationship between a compound I or II in free form and in the form of the salts thereof, a free compound I or II, or the salts thereof, respectively, is to be understood analogously above and subsequently in the present , to mean, if appropriate, also the corresponding salts and the free compounds I or II, respectively. In general, the free form is preferred in each case. In the case of salts, the veterinarily acceptable salt forms are preferred. Compounds II, where -X- is C = N-O-R10, can be presented as non-isomers or anti-isomers with respect to the C = N double bond. According to the invention, both forms are included, both the pure isomers and the mixtures of isomers. Unless defined otherwise, the general terms used previously and subsequently herein have the meanings given below. Halogen - as a group by itself and as a structural unit of other groups and compounds, such as haloalkyl, halocycloalkyl, halocycloalkoxy and haloalkoxy -, is fluorine, chlorine, bromine or iodine, especially fluorine, chlorine or bromine, more especially fluorine or chlorine. Unless defined otherwise, the groups and compounds containing carbon atoms, each preferably contain from 1 to, and including 20, more preferably from 1 to and including 18, most preferably from 1 to and including 10, especially from 1 up to and including 6, more especially from 1 up to and including 4, especially from 1 up to and including 3 carbon atoms. Alkyl - as a group by itself, and as a structural unit of other groups and compounds, such as haloalkyl, alkoxy, alkoxyalkyl, arylalkyl and haloalkoxy -, is straight chain, for example, methyl, ethyl, normal propyl, butyl normal, normal hexyl, normal octyl, normal decyl, normal dodecyl, normal hexadecyl or normal octadecyl, or branched chain, for example, isopropyl, isobutyl, secondary butyl, tertiary butyl, isopentyl, neopentyl or isohexyl. Alkenyl - as a group by itself and as a structural unit of other groups and compounds, such as alkenyloxy -, is straight chain or branched, for example, vinyl, 2-methylvinyl, allyl, but-1-en-yl or isopropenyl, especially allyl. Alkynyl - as a group by itself and as a structural unit of other groups and compounds, such as alkynyloxy -, is straight chain or branched, for example, ethynyl, prop-1-yn-l-yl, propargyl or butyl -l-in-3-yl, especially propargyl. The groups and compounds containing carbon substituted by halogen, such as haloalkyl, halocycloalkyl, haloxycycloalkoxy and haloalkoxy may be partially halogenated or perhalogenated, and, in the case of multiple halogenation, the halogen substituents may be identical or different. Examples of haloalkyl - as a group by itself and as a structural unit of other groups and compounds, such as haloalkoxy -, are methyl substituted by one to three fluorine, chlorine and / or bromine atoms, such as CHF2, CF3 or CH2C1; ethyl substituted by one to five fluorine, chlorine and / or bromine atoms, such as CH2CF3, CF2CF3, CF2CC13, CF2CHC12, CF2CHF2, CF2CFC12, CH2CH2C1, CF2CHBr2, CF2CHCIF, CF2CHBrF or CCIFCHCIF; propyl or isopropyl substituted by one to seven fluorine, chlorine and / or bromine atoms, such as CH2CHBrCH2Br, CF2CHFCF3, CH2CF2CF3, CF2CF2CF3, CH (CF3) or CH2CH2CH2C1; and butyl or one of its isomers; substituted by one to nine fluorine, chlorine and / or bromine atoms, such as CF (CF3) CHFCF3, CF2 (CF2) 2CF3 or CH2 (CF2) 2CF3. Examples of halocycloalkyl - as a group by itself and as a structural unit of other groups and compounds, such as halocycloalkoxy -, are 2,2-difluorocyclopropyl or 2,2-dichlorocyclopropyl. Cycloalkyl - as a group by itself and as a structural unit of other groups and compounds, such as halocycloalkyl, halocycloalkoxy and cycloalkoxy -, is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or cyclooctyl. Cyclopropyl is preferred. Aryl - as a group by itself and as a structural unit of other groups and compounds, such as aryloxy -, is preferably phenyl or naphthyl, especially phenyl. Alkoxyalkyl is preferably alkyl substituted by two, or preferably an alkoxy radical, for example, ethoxymethyl or 2-methoxyethyl. Arylalkyl is preferably alkyl substituted by two, or preferably an aryl radical, for example, benzyl or 2-phenylethyl. Heteroaryl in the heteroaryloxy radicals is preferably an aromatic monocyclic or bicyclic ring system, which system comprises one or two rings, selected from the group consisting of 5 and 6 membered rings, whose system is unsubstituted or substituted by one or two substituents, selected from the group consisting of halogen, nitro, alkoxy of 1 to 8 carbon atoms, haloalkoxy of 1 to 8 carbon atoms, cyano, hydroxy, alkyl of 1 to 8 carbon atoms, and haloalkyl of 1 to 8 carbon atoms, and whose system contains 1 or 2 heteroatoms, selected from the group consisting of nitrogen, oxygen and sulfur atoms. Preferred are ring systems having one or two ring nitrogen atoms, especially pyridyl, pyrimidyl and quinolyl, more especially unsubstituted pyridyl or pyrimidyl, chloropyridyl, trifluoromethylpyridyl, nitropyridyl, chlorotrifluoromethylpyridyl and chloroquinolyl. Heterocyclyl is, for example, heteroaryl, for example, as defined hereinabove, or is preferably a non-aromatic monocyclic ring system, preferably of 5 or 6 members, whose system is unsubstituted or is preferably substituted by 1 to 4 substituents, selected from the group consisting of halogen, alkyl of 1 to 8 carbon atoms, haloalkyl of 1 to 8 carbon atoms, alkoxy of 1 to 8 carbon atoms, haloalkoxy of 1 to 8 carbon atoms, hydroxy, nitro, cyano and unsubstituted heterocyclyloxy or tetra-substituted mono-a, the substituted heterocyclyloxy substituents being selected from the group consisting of alkyl of 1 to 8 carbon atoms, alkoxy of 1 to 8 carbon atoms, and hydroxy, and whose system contains 1 or 2 heteroatoms, selected from the group consisting of nitrogen, oxygen and sulfur atoms. Preferred are ring systems having an oxygen atom of the ring, such as octacyclopentyl, or preferably oxacyclohexyl, especially the 4- (α-L-oleandrosyl) -a-oleandrose group. An aryl, aryloxy, alkyl, alkoxy, alkenyl or substituted alkynyl group carries, for example, two, or preferably a substituent, selected, for example, from the group consisting of halogen, alkyl of 1 to 8 carbon atoms, haloalkyl of 1 to 8 carbon atoms, alkoxy of 1 to 8 carbon atoms, haloalkoxy of 1 to 8 carbon atoms, hydroxy, nitro and cyano. Within the scope of the present invention, a corresponding composition comprising, as an active ingredient, on the one hand, at least one compound of Formula I, selected from any of the following groups (1) to (11) is especially preferred. : (1) a compound of Formula I, wherein R? is halogen, especially fluorine, more especially where (R?) m is 2,6-difluor; (2) a compound of Formula I, wherein R 2 is halogen, haloalkyl of 1 to 4 carbon atoms, haloalkoxy of 1 to 4 carbon atoms, or substituted pyridyloxy, and n is 1, 2, 3 or 4, especially in where R2 is fluorine, chlorine, haloalkoxy of 1 to 3 carbon atoms, or chlorotrif luoromethylpyridyloxy; (3) the compound l- [2, 5-dichloro-4- (1, 1, 2, 3, 3, 3-hexaf luoroprop-1-oxy) -phenyl] -3- (2,6-difluorobenzoic acid 1 ) -urea (Lufenuron); (4) the compound l- [3- (3-chloro-5-trifluoromethyl-pyrid-2-yloxy) -4-chlorophenyl] -3- (2,6-difluorobenzoic acid) (Fluazuron); (5) the compound l- (4-chlorophenyl) -3- (2,6-difluoro-benzoyl) -urea (Dif lubenzuron); (6) the compound 1- [3,5-dichloro-4- (1,1,2,2-tetrafluoroethoxy) -phenyl] -3- (2,6-difluorobenzoyl) -urea (Hexaf lumurón); (7) the compound l- (3, 5-dichloro-2,4-dif luorofenil) -3- (2, 6-dif luorobenzoí 1) -urea (Tef lubenzurón); (8) Compound 1- [3,5-dichloro-4- (3-chloro-5-trif luoromethyl-pyrid-2-yloxy) -phenyl] -3- (2,6-dif-luorobenzoic-1-urea) luazuron); (9) the compound 1- (2-chlorobenzoyl-1) -3- (4-trifluoromethoxyphenyl) -urea (Trif lumurón); (10) the compound l- [4- (2-chloro-4-trif luoromethyl-phenoxy) -2-fluorophenyl] -3- (2,6-difluorobenzoyl) -urea (Flufenoxuron); (11) the compound l- [- (4-chloro-a-cyclopropylbenz-lidenaminooxy) -p-tolyl ] -3- (2,6-difluorobenzoyl) -urea (Flucycloxuron) and, on the other hand, at least one compound of Formula II selected from any of the following groups (12) to (21) ): (12) a compound of Formula II, wherein R5 is methyl, ethyl, isopropyl or secondary butyl, especially methyl or ethyl; (13) a compound of Formula II, wherein -X- is H "-O - g 3 and R6 is hydrogen or methyl, especially hydrogen; (14) a compound of Formula II, wherein -X- is C = NO-R10, and R10 is hydrogen or methyl, espe tially hydrogen; (15) a compound of Formula II wherein R8 is hydrogen, or the group 4- (a-L-oleandrosyl) -a-L-oleandrose, especially hydrogen; (16) a compound of Formula II, wherein the bond between atoms 22 and 23 is a single bond, and R7 is hydrogen; (17) a compound of Formula II, wherein R5 is methyl, ethyl or isopropyl, especially methyl or ethyl, -X- is C = N-0-H, R7 and R8 are hydrogen, and the bond between atoms 22 and 23 is a single bond; (18) a mixture of two compounds of Formula II, wherein -X- is C = N-0-H, R7 and. R8 are hydrogen, the bond between atoms 22 and 23 is a single bond, and at about 20 weight percent of the mixture, R5 is methyl, and at about 80 weight percent of the mixture R5 is ethyl; (19) a compound of Formula II, wherein -X- is H ^ ¿-O-H ^ R7 and R8 are hydrogen, the bond between atoms 22 and 23 is a single bond, and - R 5 is methyl (milbemycin A3), or - R 5 is ethyl (milbemycin A4), or - R 5 is isopropyl (milbemycin D); (20) a compound of Formula II, wherein -X- is H > - "0-CH * 8 is e 9ruP ° 4- (α-oleandrosyl) -aL-olenadrose, and 3 ta) the bond between atoms 22 and 23 is a single bond, R7 is OH, and - R is isopropyl ( aver ectin A2b), or - R5 is secondary butyl (avermectin A2a), or (b) the bond between atoms 22 and 23 is a double bond, R7 is H, and - R5 is isopropyl (avermectin Alb), or - R5 is secondary butyl (Ala avermectin); (21) a compound of Formula II, wherein -X- is is the group 4- (α-oleandrosyl) -aL-olenadrosa, already) the bond between atoms 22 and 23 is a single bond, R7 is OH, and - R5 is isopropyl (avermectin B2b), or - 5 is secondary butyl (avermectin B a); b) the bond between atoms 22 and 23 is a double bond, R7 is H, and - R5 is isopropyl (avermectin Blb), or - R5 is secondary butyl (avermectin Bla); Very particularly preferred within the scope of the present invention is a corresponding composition, comprising, as an active ingredient, any of: (22) Lufenuron and a mixture of two compounds of Formula II, wherein -X- is C = N-0-H, R7 and R8 are hydrogen, the bond between atoms 22 and 23 is a single bond, and R5 is on the one hand methyl, and on the other part ethyl; or (23) Fluazuron and a mixture of two compounds of the formula II, wherein -X- is C = N-0-H, R7 and R8 are hydrogen, the bond between the atoms 22 and 23 is a single bond, and R5 is on the one hand methyl, and on the other part ethyl; or (24) Lufenuron and milbemycin oxime. The compounds of Formulas I and II are known or can be prepared according to methods that are known per se. Specifically: - Lufenuron is known from the European Patent Number EP-B1-0 179 022; Fluazuron is known from European Patent Number EP-A-0 079 311; Diflubenzuron is known from The Pesticide Manual, 92 Edition (1991), The British Crop Protection Council, London, page 281; Teflubenzuron is known from The Pesticide Manual, 9th Edition (1991), The British Crop Protection Council, London, page 790; - Clorfluazuron is known from The Pesticide Manual, 9th Edition (1991), The British Crop Protection Council, London, page 143; Hexaflumuron is known from The Pesticide Manual, 9 * Edition (1991), The British Crop Protection Council, London, page 471; Triflumuron is known from The Pesticide Manual, The Edition (1994), The British Crop Protection Council, London, page 1023; Flufenoxuron is known from The Pesticide Manual, 10th Edition (1994), The British Crop Protection Council, London, page 483; Flucycloxuron is known from The Pesticide Manual, 10th Edition (1994), The British Crop Protection Council, London, page 478; - the compounds of Formula II, where -X- is C = N-0-H, R7 and R8 are hydrogen, the bond between atoms 22 and 23 is a single bond, and R5 is methyl or ethyl, are known under the terms of milbemycin oxime A3 (methyl derivative), and milbemycin oxime A4 (ethyl derivative), respectively, and are described in European Patent EP-B1 -0 110 667; milbemycin A3 and milbemycin A4 are known from the patent of the United States of America number US-3,950,360; milbemycin D is known from the patent of the United States of North America US-4, 346, 171; and avermectin Ala, avermectin Alb, avermectin A2a, avermectin A2b, avermectin Bla, avermectin Blb, avermectin B2a and avermectin B2b are described in German Patent DE-OS 27 17 040. Surprisingly, the composition according to the invention is outstandingly suitable for controlling in a curative manner, and surprisingly, also in a preventive manner, a very convenient spectrum of parasites within and on animals, even at low application concentrations, while being well tolerated, for example, by warm-blooded animals, fish and plants. The composition according to the invention is effective against all or the individual developmental stages of the parasites of normally sensitive and also resistant animals, such as insects, representatives of the order Acariña, or parasitic worms, such as helminths. The good pesticidal activity of the composition according to the invention can be manifested directly, ie, in the death of the parasites, which occurs immediately, or only at a later date, or indirectly, for example, in a reduced oviposition and / or reduced hatching rates of the corresponding parasites, the good activity corresponding, for example, to a mortality and / or to a reduction in oviposition and / or in the hatching rate of at least 50 to 60 percent. Parasites that can be controlled with the composition according to the invention include, for example: of the order Acariña, for example, representatives of the families Argasidae, Dermanyssidae, Ixodidae, Psoroptidae or Sarcoptidae and representatives of the species Amblyomma spp. , Anocentor spp., Argas spp., Boophilus spp., Cheyletiella spp., Chorioptes spp., Demodex spp., Dermacentor spp., Dermanyssus spp., Haemophysalis spp., Hyalomma spp., Ixodes spp., Lynxacarus spp., Notoedres spp., Ornithodoros spp., Ornithonyssus spp., Otobius spp., Otodectes spp., Pneumonyssus spp., Psoroptes spp., Rhipicephalus spp. or Sarcoptes spp.; of the order Anoplura, for example, representatives of the species Hae atopinus spp., Linognathus spp., Pediculus spp., Pemphigus spp. or Phylloxera spp. of the order Diptera, for example, representatives of the species Aedes spp., Anopheles spp., Calliphora spp., Chrysomyia spp., Chrysops spp., Cochliomyia spp., Culex spp., Culicoides spp., Cuterebra spp., Dermatobia spp. ., Gastrophilus spp., Glossina spp., Haematobia spp., Haematopota spp., Hippobosca spp., Hypoderma spp., Lucilia spp., Lyperosia spp., Melophagus spp., Oestrus spp., Phlebotomus spp., Phormia spp., Sarcophaga spp., Simuliu spp., Stomoxys spp., Tabanus spp., Tannia spp. ó Typula spp.; of the Malofaqa order. for example, representatives of the species Damalina spp., Felicola spp., Heterodoxus spp. or Trichodectes spp.; of the Nematode class. for example, representatives of the families Filariidae or Setariidae, representatives of the genera Asearis, Bunostomum, Chabertia, Cooperia, Haemonchus, Nematodirus, Oesophagostomum, Ostertagia, Tichostrongylus or Trichuris, and representatives of the species Ancylostoma spp., Ascaridia spp., Capillaria spp. ., Dictyocaulus spp., Dirofilaria spp., Heterakis spp., Oxyuris spp., Parascaris spp., Strongyloides spp., Strongylus spp., Toxascaris spp., Toxocara spp., Trichonema spp., Trichuris spp. or Uncinaria spp .; of the Siphonaptera order, for example, representatives of the species Ceratophyllus spp., Ctenocephalides spp., or Xenopsylla spp.; and of the Tremátoda class, for example, representatives of the Fasciolidae family and representatives of the Fasciola spp. These parasites infest numerous animals, especially warm-blooded, for example, domestic animals, such as calves, cats, cattle, cows, dogs, goats, horses, pigs, poultry or sheep, which can be treated with the composition in accordance with the invention Especially, by means of the composition according to the invention, Ctenocephalides canis and / or C. felis are controlled simultaneously with Ancylostoma caninum, Dirofilaria immitis, Toxocara canis and / or Trichuris vulpis; very especially, by means of the composition according to the invention, C. felis and D. im itis are controlled simultaneously on and within dogs. In particular, it has been discovered in a surprising manner, that the parasiticidal activity of the composition according to the invention, when compared to the combined parasiticidal activities of the individual compounds I and II, together forming the active ingredient of the present composition, it is not only additive, as can be expected in principle, but also shows a surprising synergistic effect. In this connection, the term "synergistic effect" is not limited to the pure parasiticidal activity against a certain species of parasite, nor is it necessary that this term be entirely related to the pure parasiticidal activity, but that this term can be related to any property of the present composition, which is convenient, when compared with the corresponding combined properties of the individual compounds I and II, together forming the active ingredient of the present composition. As examples of these convenient properties of the present composition, there may be mentioned: an extension in the spectrum of parasiticidal activity towards additional or different parasites, for example, towards a resistant parasite species. A reduction in the application concentrations of compounds I and / or II; a sufficient degree of parasite control by means of the present composition, even in cases where the individual compounds I and II which together form the active ingredient of the present composition, are totally ineffective due to their extremely low application concentrations. A suitable behavior in case they are formulated and / or applied, for example, being milled, sieved, compressed, emulsified, dissolved, dispersed or pulverized; better storage stability; better stability to light; better stability to heat; a suitable behavior in the case of degrading; a better toxicology profile; a better ecotoxicological behavior; and other family advantages for experts in this field. Surprisingly, with the aid of specific methods of administration to animals, for example, by external treatment with, but especially by systemic administration of, a composition according to the invention, it is possible to eliminate the aforementioned ectoparasites very quickly and completely, and in this way obstructively intervene in the complex life cycle of these parasites, and at the same time achieve effective control of the aforementioned endoparasites. Since the composition according to the invention still exhibits its excellent parasiticidal effect completely when administered to the host animal in a systemic manner, i.e., orally, parenterally or by implant, it is possible, by a controlled periodic administration of the composition, to interrupt the continuously recurrent reinfestation described of the host animal by the different parasites in a simple manner, until all the stages of the young parasites are controlled in the area where the host animal lives. The parasites are annihilated and prevented from reproducing, and the juvenile stages are prevented from reaching adulthood, and they can no longer infest the host animal, as a result of which, the area where the host animal lives can be kept free. of parasites in a permanent way. Accordingly, the present invention further relates to a method for controlling parasites within and on animals, for example, domestic animals and producer cattle, which comprises administering the host animals, a composition according to the invention, in a parasiticidally effective amount, preferably systemically, i.e., orally, parenterally or by implantation. A special form of this method comprises administering the different compounds of active ingredient I and II to be used, to the host animal, in a parasiticidally effective amount, not simultaneously, but within a short interval, i.e., within a week at the most, especially on the same day.

In this method, there is no difference if the modes of administration are identical, that is, if the active ingredient compounds are all administered, for example, orally, or are different, that is, if one or more of the active ingredient compounds they are administered, for example, orally, and others are administered, after a short interval, for example, parenterally. What is very remarkable with respect to the present invention, is that a total effect is still achieved, even when the composition according to the invention is administered to the host animal in relatively low concentrations. When the endoparasites and the ectoparasites are completely and simultaneously annihilated after the systemic administration of the composition, it is now possible to achieve the simultaneous elimination of the parasites. By combining this systemic use of the composition with secondary measures, such as disinfection of the host animal's place, it is possible to dispose of the parasite problem even more quickly; however, even without these secondary measures, the population of the parasite will be completely reduced, or at least to an acceptable minimum within a few weeks, or at most months. Consequently, complex life cycles, for example, fleas and ticks, are interrupted, and continuous reinfestation of the host animals in their preferred area of life is prevented by the eggs that are dispersed anywhere, and by the larvae that emerge from them. The way in which parasites are controlled is that, although the eggs are laid by adults who are completely replete with blood, which in the case of ticks, they fall from the host animal, but in the case of fleas, they remain the host animal, there are no larvae, or there are only a few larvae that can develop from those eggs. Although these few larvae in turn can infest the host animal, they can not develop further, so the cycle is broken. Accordingly, the composition according to the invention has especially a preventive effect against the different types of parasites, but also has a curative effect as regards, for example, the larvae of ticks that are on the host animal, but they have not yet ingested any active substance by means of the cycle described, which is prevented from further developing in adults upon the treatment of the host with a poured or greased local formulation. An important advantage of the method according to the invention resides in the fact that the life cycle of the carriers is also interrupted. These carriers are, for example, different species of mosquitoes that are responsible for transmitting endoparasites, such as Filariae. It is essential that the composition according to the invention be administered in such a way that compounds I and II can be ingested by endoparasites, ectoparasites and also by other pests, which come into consideration as vectors for the transmission of endoparasites, with the blood of the animal host in a sufficient amount so that the eggs laid by the adults, and also the larvae, no longer develop. This is achieved with the composition according to the invention, using different administration forms, for example, by administering the orally formulated composition. "Formulated" means, in this case, for example, in the form of a powder, a tablet, a granule, a capsule, a dragee, an emulsion, a foam, in a microencapsulated form, etc., without having to give necessarily the formulation to the animal directly, but conveniently mixes with its food. All the compositions that are to be orally administered, of course, may contain, in addition to the customary formulation aids, also other additives that encourage the voluntary ingestion of the composition by the host animal., for example, suitable flavors. Due to its easy practicability, oral administration is one of the preferred objects of this invention. Other modes of administration are parenteral administration, for example, subcutaneous or intravenous injection, and as a long-term formulation (depot form), application in the form of an implant or in the form of an injection of icrocapsules (referred to as "microspheres"). Oral administration also includes, for example, the portion of the animal feed, for example, dog or cat food, which already contains the active ingredient mixed with it, for example, in the form of biscuits, lozenges, capsules or capsules. water-soluble tablets, in a water-soluble form that can be added in drops to food, or in other forms that can be mixed with animal feed. The administration of veterinary medicine additives to animal feed is better known in the animal health sector. Normally, a so-called premix is first prepared, where the active substances are dispersed in a liquid, or finely distributed in solid vehicles. This pre-mix can normally comprise, depending on the final desired concentration in the food, from about 0.1 to 800 grams of the active substances per kilogram of the premix. In addition, it is known that the active substances can be hydrolyzed or made weaker by the ingredients of the food. These active substances are routinely formulated in a protective matrix, for example, in gelatin, before being added to the premix. Parenteral administration includes, for example, subcutaneous, dermal, intramuscular, and even intravenous administration of injectable formulations. Apart from conventional syringes with needles, needle-free pressure gun devices, as well as spilled and greased formulations, may be useful for this purpose. By selecting a suitable formulation, it is possible to improve the penetrability of the active ingredient through the live tissue of the animal, and maintain its availability. This is important when, for example, one or more sparingly soluble active substances are used, whose low solubility requires a measure that promotes solubility, since the animal's body fluid can dissolve only small amounts of the active substances all at once. . The active substances can also be present in a matrix formulation that, by means of a physical element, prevents its decomposition and maintains its constant availability. This matrix formulation is injected into the body and remains there as a kind of deposit, from which the active substances are continuously released. These matrix formulations are known to those skilled in the art. In general, they are semisolid excipients in the form of wax, for example, vegetable waxes, polyethylene glycols having a high molecular weight, or copolymers of degradable polyesters. High availability of the active ingredient is also obtained by inserting an implant of the active substances into the animal. The implants include all the devices that can be inserted into the body of the animal to release the substances. These implants are widely used in veterinary medicine, and often consist of silicone-containing rubber. The active substances are dispersed in the solid rubber, or they are located inside a hollow rubber body. Care must be taken to select active substances that are soluble in the rubber implant, since they first dissolve in the rubber, and then they are continuously filtered from the rubber material into the body fluid of the animal to be treated. The rate of release of the active substances from the implant and, therefore, the period during which the implant is effective, are generally determined by the precision of the calibration (amount of active ingredient in the implant) of the implant., the implant environment, and the polymer formulation, from which the implant is made. Administration of the active ingredient by means of an implant is another preferred component of the present invention. The administration in this way is extremely economical and effective, since a correctly dimensioned implant ensures a constant concentration of the active substances in the tissue of the host animal. The implants can now be configured and can be easily implanted, so that they are able to apply the active ingredients for a number of months. Compounds I and II are each conveniently administered to the animal in a dose of about 0.01 to 800, preferably about 0.1 to 200, especially about 0.5 to 30 milligrams / kilogram of body weight. The dose may vary for the same active ingredient from one animal genus to another, and also within an animal genus, since it depends, among other things, on the weight and constitution of the animal. A suitable dose to be administered regularly to the host animal is, for example, in the case of a cat, a dose of 30 milligrams / kilogram of body weight of a compound I, and 2 milligrams / kilogram of body weight of a compound II , and in the case of a dog, a dose of 10 milligrams / kilogram of body weight of a compound I, and 0.5 milligrams / kilogram of body weight of a compound II. The administration is conveniently done every week, or especially every month. The combination of active substances according to the invention comprises at least one compound I and at least one compound II, preferably in a proportion [compound (s) I: compound (s) II] of 1:60 to 60: 1, especially from 1:20 to 20: 1, more especially from 10: 1 to 1:10, most especially from 5: 1 to 1: 5, and most preferably from 2: 1 to 1: 2. Especially preferred proportions [compound (s) I: compound (s) II] are 20: 1, or 15: 1, or 5: 1, or 4: 1, or 3: 1, or 2 1, or 1: 1, or 1: 2, or 1: 3, or 1: 4, or 1: 5, or 5: 2, or 3: 2, or 4: 3 , or 3: 4, or 2: 3, or 5: 3, or 3: 5, or 5: 4, or 4: 5. The composition according to the invention usually comprises from 0.1 to 99 weight percent, preferably from 0.1 to 95 weight percent of compounds I and II, and from 99.9 to 1 weight percent, preferably from 99.9 to 5 percent by weight, of a solid or liquid auxiliary. As formulation aids, the known materials of veterinary medicine for oral or parenteral administration or for implants can be used preferably. Subsequently, a number of examples are mentioned herein. Suitable carriers are especially fillers, such as sugars, for example, lactose, sucrose, mannitol or sorbitol, cellulose preparations or calcium phosphates, for example, calcium triphosphate or calcium acid phosphate, and also binders, such as pastes of starch, using, for example, corn, wheat, rice or potato starch, gelatin, tragacanth, methyl cellulose or, if desired, disintegrants, such as the aforementioned starches, also carboxymethyl starch, cross-linked polyvinyl pyrrolidone, agar or alginic acid or a salt thereof, such as sodium alginate. The excipients are especially flow conditioners and lubricants, for example, silicic acid, talc, stearic acid or salts thereof, such as magnesium or calcium stearate, or polyethylene glycol. Dragee cores can be provided with suitable, optionally enteric coatings, using, inter alia, concentrated sugar solutions which may comprise gum arabic, talc, polyvinyl pyrrolidone, polyethylene glycol or titanium dioxide, or solvent coating solutions. suitable organic or solvent mixtures, or, for the preparation of enteric coatings, solutions of suitable cellulose preparations, such as acetyl cellulose phthalate or hydroxypropylmethyl cellulose phthalate. Dyes, flavors or pigments may be added to tablets or dragee coatings, for example, for identification purposes, or to indicate different doses of the active ingredient. Other orally administrable compositions are dry filled capsules made of gelatin, and also sealed soft capsules made of gelatin and a plasticizer, such as glycerol or sorbitol. The dry-filled capsules may comprise the active ingredient in the form of granules, for example, mixed with fillers, such as lactose, binders, such as starches, or brighteners, such talc or magnesium stearate, and if desired, stabilizers. In soft capsules, the active ingredient is preferably dissolved or suspended in suitable liquids, such as fatty oils, paraffin oil or liquid polyethylene glycols, to which stabilizers may also be added. Preferred are, among other things, the capsules, which can be easily bitten and swallowed without chewing. Suitable for parenteral administration are especially the aqueous solutions of the active ingredient in a water-soluble form, for example, in the form of water-soluble salts, or else suspensions of the active ingredient, such as corresponding oily injection suspensions, using solvents or vehicles. suitable lipophilics, such as fatty oils, for example, sesame oil, or synthetic fatty acid esters, for example, ethyl oleate or triglycerides, or aqueous injection suspensions comprising viscosity-increasing substances, for example, sodium carboxymethyl cellulose , sorbitol or dextran, and if desired, also stabilizers. The formulations may also comprise other auxiliaries, such as binders, antifoams, viscosity regulators, stabilizers and also viscosifiers. The composition according to the invention can be prepared in a manner known per se, for example, by means of conventional mixing, granulating, confectionery, dissolving or lyophilizing processes. For example, a veterinary composition for oral administration can be obtained by combining the active ingredient with solid carriers, if desired the resulting mixture is granulated, and the mixture or granules are processed, if desired or necessary, after administration. addition of the appropriate excipients, to form tablets or dragee cores. The following Examples illustrate the invention described above, but do not limit its scope in any way. Temperatures are given in degrees Celsius. Formulation Examples In the following Formulation Examples, "active ingredient I" denotes one or more compounds I, and "active ingredient II" denotes one or more compounds II, in each case in free form or in an acceptable veterinary salt form. .

Example 1: Tablets Composition (for 1,000 tablets) active ingredient I 25 grams active ingredient II 1.25 grams lactose 100.7 grams wheat starch 6.25 grams polyethylene glycol 6000 5.0 grams talc 5.0 grams magnesium stearate 1.8 grams demineralized water q.s.

Preparation: All solid ingredients are first forced through a sieve with a mesh size of 0.6 mm. Then the active ingredients, lactose, talc and half of the starch are mixed. The other half of the starch is suspended in 40 milliliters of water, and the suspension is added to a boiling solution of polyethylene glycol in 100 milliliters of water. The resulting starch paste is added to the main ingredients, and the mixture is granulated, if necessary with the addition of water. The granules are dried overnight at 35 ° C, forced through a sieve of a mesh size of 1.2 millimeters, mixed with the magnesium stearate, and compressed to form biconcave tablets of a mesh size of approximately 6 mm.

Example 2; Tablets Composition (for 10,000 tablets): active ingredient I 180.0 grams active ingredient II 3.0 grams lactose 280.8 grams potato starch 274.7 grams stearic acid 10.0 grams talcum 217.0 grams magnesium stearate 2.50 grams colloidal silica 32.0 grams ethanol CS A mixture of the active ingredients , lactose and 200 grams of potato starch, is moistened with an ethanolic solution of stearic acid, and granulated through a sieve. After the granules are dried, the rest of the potato starch, talc, magnesium stearate and colloidal silica are added, and the mixture is compressed to form tablets, each weighing 0.1 grams, to which, if you want, you can provide notches to cut, for a finer adjustment of the dose.

Example 3: Capsules Composition (for 1,000 capsules) active ingredient I 20.0 grams active ingredient II 2.0 grams lactose 249.8 grams gelatin 2.0 grams corn starch 10.0 grams talcum 15.0 grams water q.s. The active ingredients are mixed with the lactose, and the mixture is uniformly moistened with an aqueous solution of the gelatin, and granulated through a sieve having a mesh size of 1.2 to 1.5 millimeters. The granules are mixed with the dried corn starch and talc, and 300 mg portions are filled into hard gelatin capsules (size 1).

Example 4; Premix (feed additive) 0.15 parts by weight of the active ingredient I, 0.01 parts by weight of the active ingredient II, and 4.84 parts by weight of secondary calcium phosphate, clay soil, aerosol, carbonate or chalk, are mixed with 95 parts by weight. weight of an animal feed until it is homogeneous.

Example 5; Premix (food additive) 0.40 parts by weight of the active ingredient I, 0.01 parts by weight of the active ingredient II, and 5.00 parts by weight of Aerosil / chalk (1: 1), are mixed with 94.59 parts by weight of a dry food commercial, until homogeneous.

Example 6: Emulsifiable Concentrate 20 parts by weight of the active ingredient I, and one part by weight of the active ingredient II are mixed with 20 parts by weight of the emulsifier (mixture of alkylaryl polyglycol ether with alkylaryl polysulfonates) and 59 parts by weight of a suitable solvent, until the solution has been completely homogenized. Emulsions of the desired concentration can be obtained by dilution with water.

Example 7: Soluble Powder 25 parts by weight of the active ingredient I, 0.5 parts by weight of the active ingredient II, 2.5 parts by weight of sodium lauryl sulfate, 3 parts by weight of colloidal silica gel, and 69 parts by weight of urea , mix and grind together until they are homogeneous.

Other biologically active substances, or additives which have a neutral behavior towards the active ingredients, and which do not have a harmful effect on the host animal to be treated, or also mineral salts or vitamins, can be added to the compositions described.

Biological Examples (unless otherwise defined,% = percent by weight).

Example 8: Simultaneous action against Ancylostoma caninum? Ctenocephalides felis. As test animals, 3 dogs (1 female, 2 males) of 7 to 10.5 kilograms of body weight, and 2 to 3 years of age are used. As comparison animals, 3 dogs (1 female, 2 males) of 7.5 to 10 kilograms of body weight, and 2 to 4 years of age are used. All animals are naturally infected with Ancylostoma caninum. Immediately after the administration of a gelatin capsule comprising 10 milligrams / kilogram of body weight of Lufenuron, and 0.5 milligram / kilogram of body weight of Milbemycin oxime, each of the test animals is infested in the neck region with 20 fleas of the species Ctenocephalides felis (16 female fleas and 4 male fleas). The comparison animals are not given active substances, but they are infected in the same way and at the same time with Ctenocephalides felis. During the trial period, flea eggs are collected daily and incubated to determine their viability. A first evaluation of the endoparasites is made by comparing the number of worms excreted by the test animals and by the control animals. Already a few days after the treatment, the hatching of the flea eggs and the development of adult fleas are completely suppressed. An autopsy reveals that the test animals are completely free of worms. In untreated animals, there is no significant reduction in the ability of flea eggs to develop, nor a reduction in the number of worms in the gastrointestinal tract.

Example 9; Simultaneous action against Ctenocephalides felis and Dirofilaria immitis. As test animals, 3 dogs (1 female, 2 males) of 7.5 to 10.2 kilograms of body weight, and 2 to 4 years of age are used. As comparison animals, 3 dogs (1 female, 2 males) of 7.0 to 10.1 kilograms of body weight, and 2 to 4 years of age are used. The test animals are infected subcutaneously with 40 infective larvae (3rd larval stage) of Dirofilaria immitis, obtained from infected mosquitoes (Aedes aegypti). Thirty days later, the test animals are given a gelatin capsule comprising 10 milligrams / kilogram of body weight of Lufenuron, and 0.5 milligrams / kilogram of body weight of Milbemycin oxime, and immediately after, each of the test animals are infested in the neck region with 20 fleas of the species Ctenocephalides felis (16 female fleas and 4 male fleas). The comparison animals are not given active substances, but they are infected in the same way and at the same time with Dirofilaria immitis and Ctenocephalides felis. Already a few days after the treatment, the hatching of the flea eggs and the development of adult fleas in the test animals are completely suppressed. After autopsy 200 days after infection, adult heart worms are no longer found in the lungs and in the hearts of treated animals. In the untreated control group, there are an average of 20 adults of Dirofilaria immitis per test animal.

Claims (20)

1. NOVELTY OF THE INVENTION
2. Having described the foregoing invention, it is considered as a novelty and, therefore, the content of the following is claimed as property:
3. CLAIMS 1. A composition for controlling parasites, in and on animals, which comprises, as an active ingredient, an effective amount of a combination, in varying proportions, of at least one parasiticidally active compound, in free form or in salt form, selected from the class of substances of N-phenyl-N'-benzoyl-urea, and at least one parasiticidally active compound, in free form or in salt form, selected from the classes of substances of milbemycin, avermectin, milbemycin oxime, moxidectin, ivermectin, abamectin and doramectin. 2. A composition according to claim 1, which comprises, as an active ingredient, at least one compound of the Formula:
4. (I), wherein: Rj ^ is halogen, alkyl of 1 to 8 carbon atoms, cycloalkyl of 3 to 8 carbon atoms, halocycloalkyl of 3 to 8 carbon atoms, haloalkyl of 1 to 8 carbon atoms, alkoxy of 1 to 8 carbon atoms, alkoxy of 1 to 4 carbon atoms-alkyl of 1 to 4 carbon atoms, or haloalkoxy of 1 to 8 carbon atoms; R2 is halogen, alkyl of 1 to 8 carbon atoms, cycloalkyl of 3 to 8 carbon atoms, haloalkyl of 1 to 8 carbon atoms, halocycloalkyl of 3 to 8 carbon atoms, alkoxy of 1 to 8 carbon atoms, cycloalkoxy from 3 to 8 carbon atoms, halocycloalkoxy of 3 to 8 carbon atoms, haloalkoxy of 1 to 8 carbon atoms, aryloxy or heteroaryloxy, aryloxy or substituted heteroaryloxy, or a group -CH2-0-N = C (R3) R4; R3 and R4 are each, independently of the other, alkyl of 1 to 4 carbon atoms, cycloalkyl of 3 to 8 carbon atoms, or aryl, each of which is unsubstituted or substituted; m is from 0 to 5, where, when m is greater than 1, the radicals R? they are the same or different; and n is from 0 to 5, wherein, when n is greater than 1, the radicals R2 are the same or different; in free form or in salt form, and at least one compound of the formula: wherein: R5 is alkyl of 1 to 4 carbon atoms, or alkenyl of 2 to 4 carbon atoms; the bond between atoms 22 and 23 is a single bond or a double bond, H -X- is a group > -0-Rß. -0 or. = N-0-R10;
5. R6 is hydrogen, alkyl of 1 to 8 carbon atoms, unsubstituted or substituted, unsubstituted or substituted aryl, -C (= 0) R17 or -Si (R18) (R19) (R20); R7 is hydrogen or hydroxy, where R7 is hydrogen when the bond between atoms 22 and 23 is a double bond; Rβ is hydrogen, alkyl of 1 to 8 carbon atoms, alkenyl of 2 to 8 carbon atoms, alkynyl of 2 to 8 carbon atoms, aryl, substituted aryl, or a group -0R9 or -SR9; R9 is alkyl of 1 to 8 carbon atoms, alkenyl of 2 to 8 carbon atoms, alkynyl of 2 to 8 carbon atoms, aryl, C (= 0) R16, alkyl of 1 to 8 carbon atoms substituted, alkenyl of 2 to 8 carbon atoms, alkynyl of 2 to 8 carbon atoms, or aryl, or unsubstituted or substituted heterocyclyl; R10 is hydrogen, alkyl of 1 to 8 carbon atoms unsubstituted or substituted, arylalkyl of 1 to 4 carbon atoms, -CH ^ orCOR- ^ or -S02-R15; R ^ is hydrogen, alkyl of 1 to 8 carbon atoms, arylalkyl of 1 to 8 carbon atoms, alkenyl of 2 to 8 carbon atoms, alkynyl of 2 to 8 carbon atoms, alkoxy of 1 to 8 carbon atoms, alkenyloxy of 2 to 8 carbon atoms, alkynyloxy of 2 to 8 carbon atoms, aryl, aryloxy -N (R12) R13, - (CH2) pCOOR14, or alkyl of 1 to 8 carbon atoms, or alkoxy of 1 to 8 carbon atoms substituted by alkoxy of 1 to 4 carbon atoms, halogen, or by nitro, or aryl, aryloxy or arylalkyl of 1 to 8 carbon atoms substituted by alkyl of 1 to 4 carbon atoms, haloalkyl of 1 to 4 atoms carbon, alkoxy of 1 to 4 carbon atoms, haloalkoxy of 1 to 4 carbon atoms, halogen, or by nitro; R12 and R13 are each, independently of the other, hydrogen, alkyl of 1 to 8 carbon atoms, phenyl, or alkyl of 1 to 8 carbon atoms, or phenyl substituted by alkoxy of 1 to 4 carbon atoms, halogen or nitro; R14 is hydrogen or unsubstituted or substituted alkyl of 1 to 8 carbon atoms; R15 is alkyl of 1 to 8 carbon atoms or aryl, each of which is unsubstituted or substituted; R16 is hydrogen, alkyl of 1 to 8 carbon atoms, alkoxy of 1 to 8 carbon atoms, or aryl, each of which is unsubstituted or substituted; R17 is hydrogen, alkyl of 1 to 8 carbon atoms, alkoxy of 1 to 8 carbon atoms, or aryl, each of which is unsubstituted or substituted; R18, R19 and R20 are each, independently of the others, alkyl of 1 to 8 carbon atoms, alkoxy of 1 to 8 carbon atoms, or aryl, each of which is unsubstituted or substituted; or is 0, 1, 2, 3 or 4; and p is 0, 1, 2, 3 or 4; in free form or in salt form. 3. A composition according to the claim 2, which comprises the active ingredient compounds of Formulas I and II in free form. 4. A composition according to the claim 3, which includes Lufenuron. 5. A composition according to the claim 3, which includes Fluazurón.
6. 6. A composition according to claim 3, which comprises Milbemycin oxime.
7. 7. A composition according to claim 3, which comprises Lufenuron and Milbemycin oxime.
8. 8. A composition according to claim 3, which comprises Fluazuron and Milbemycin oxime.
9. 9. A composition according to claim 1, which additionally comprises at least one auxiliary.
10. 10. A method for controlling parasites, in and on animals, which comprises administering a parasiticidally effective amount of a composition according to claim 1 to the host animal.
11. 11. A method according to claim 10, characterized in that the composition is administered orally, parenterally or by implant.
12. 12. A method according to claim 11, characterized in that the composition is administered orally.
13. 13. A method according to claim 12, characterized in that the composition is administered together with the animal feed.
14. 14. A method according to claim 10, characterized in that the host animal is a cat or a dog.
15. 15. A method according to claim 10, characterized in that the parasites are insects, representatives of the order Acariña or parasitic worms.
16. 16. A method according to claim 15, characterized in that ectoparasites of the species Ctenocephalides canis or Ctenocephalides felis and endoparasites of the species Ancylostoma caninum, Dirofilaria immitis, Toxocara canis or Trichuris vulpis are simultaneously controlled.
17. 17. A method according to claim 16, characterized in that ectoparasites of the species Ctenocephalides felis and endoparasites of the species Dirofilaria immitis are simultaneously controlled.
18. 18. A method according to claim 17, characterized in that the host animal is a dog.
19. 19. The use of a composition as claimed in claim 1, in a method as claimed in claim 10.
20. 20. A process for the preparation of a composition as claimed in claim 9, characterized in that the active ingredient is mix homogeneously with the auxiliaries.